SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.770
-0.160 (-4.07%)
Mar 5, 2026, 2:52 PM EST - Market open
SAB Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for SAB Biotherapeutics stock have an average target of 9.80, with a low estimate of 6.00 and a high estimate of 15. The average target predicts an increase of 159.95% from the current stock price of 3.77.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 7, 2026.
Analyst Ratings
The average analyst rating for SAB Biotherapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +85.68% | Jan 7, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +297.88% | Dec 19, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +218.30% | Dec 18, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +218.30% | Nov 17, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +218.30% | Sep 19, 2025 |
Financial Forecast
Revenue This Year
n/a
from 1.32M
Revenue Next Year
n/a
EPS This Year
-0.46
from -3.68
EPS Next Year
-0.62
from -0.46
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.48 | -0.32 | ||||
| Avg | -0.46 | -0.62 | ||||
| Low | -1.97 | -1.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.